Clinical trial
Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe…
NCT00090129 · EMD Serono, Industry · Terminated
Key facts
| NCT number | NCT00090129 |
|---|---|
| Title | Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis |
| Official title | A Multicentre, Randomised, Double-blind, Placebo Controlled Phase III Study of Subcutaneously Administered Onercept in the Treatment and Re-treatment of Subjects With Moderate to Severe Plaque Psoriasis |
| Lead sponsor | EMD Serono, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Arthritis, Psoriatic |
| Intervention type | Drug |
| Interventions | Onercept, Placebo |
| Enrollment | 854 |
| Start date | Sep 1, 2004 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Aug 26, 2004 |
| Last update posted | Oct 22, 2013 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: